Jiahui Du
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jiahui Du has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Xinquan Jiang
Department of Prosthodontics, Shanghai Stomatological Hospital & School of Stomatology, Fudan University, Shanghai, China
8 shared publications Yili Liu
Department of Prosthodontics, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200011
6 shared publications- Mingliang Zhou
Department of Prosthodontics, Shanghai Stomatological Hospital & School of Stomatology, Fudan University, Shanghai, China
5 shared publications Enhui Yao
Department of Prosthodontics, Shanghai Stomatological Hospital & School of Stomatology, Fudan University, Shanghai, China
4 shared publicationsJingyi Xu
Department of Prosthodontics, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
4 shared publicationsJinrui Sun
Department of Prosthodontics, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
4 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
Unraveling the Pathogenesis of Medication-Related Osteonecrosis of the Jaw
Medication-related osteonecrosis of the jaw (MRONJ) is a serious complication associated with bone-modifying and antiangiogenic therapies. As the use of these agents expands in osteoporosis management and cancer care, the population at risk of MRONJ is increasing. Despite its substantial clinical burden, effective prevention and treatment remain limited by an incomplete understanding of its pathogenesis and of the biological features that may confer susceptibility to the jaws. This review critically synthesizes current evidence across five potentially interacting pathogenic domains: impaired bone remodeling, compromised vascular and lymphatic support, impaired oral soft-tissue healing, microbial dysbiosis and biofilm formation, and immune dysregulation. Systemic comorbidities and concomitant therapies are also considered as potential modifiers of disease susceptibility and clinical course. In addition, we examine jaw-specific susceptibility by integrating evidence from developmental biology, comparative anatomy, cellular pharmacology, and local osteoimmune biology. Together, these observations support a multifactorial model of MRONJ in which drug-specific effects interact with local tissue characteristics and host factors, while the temporal sequence and relative contribution of individual mechanisms remain incompletely defined. A more precise understanding of these interactions may improve risk stratification and inform future preventive and therapeutic strategies.
- 2 November 2026
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
Open AccessUnraveling the Pathogenesis of Medication-Related Osteonecrosis of the Jaw
Medication-related osteonecrosis of the jaw (MRONJ) is a serious complication associated with bone-modifying and antiangiogenic therapies. As the use of these agents expands in osteoporosis management and cancer care, the population at risk of MRONJ is increasing. Despite its substantial clinical burden, effective prevention and treatment remain limited by an incomplete understanding of its pathogenesis and of the biological features that may confer susceptibility to the jaws. This review critically synthesizes current evidence across five potentially interacting pathogenic domains: impaired bone remodeling, compromised vascular and lymphatic support, impaired oral soft-tissue healing, microbial dysbiosis and biofilm formation, and immune dysregulation. Systemic comorbidities and concomitant therapies are also considered as potential modifiers of disease susceptibility and clinical course. In addition, we examine jaw-specific susceptibility by integrating evidence from developmental biology, comparative anatomy, cellular pharmacology, and local osteoimmune biology. Together, these observations support a multifactorial model of MRONJ in which drug-specific effects interact with local tissue characteristics and host factors, while the temporal sequence and relative contribution of individual mechanisms remain incompletely defined. A more precise understanding of these interactions may improve risk stratification and inform future preventive and therapeutic strategies.
- Open Access
- 10 August 2026
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (73) , e77452
Biomimetic Mitochondrial Vesicles Delivered by Lubricative Hydrogel Microspheres Enable Cartilage Repair in Osteoarthritis
Mitochondrial dysfunction in chondrocytes and the loss of joint lubrication are increasingly recognized as key pathological drivers of functional deterioration in osteoarthritis (OA). However, the rational design of multifunctional biomaterials capable of concurrently regulating bioenergetic metabolism and the joint mechanical microenvironment remains highly challenging. Inspired by the natural process of mitochondrial‐derived vesicles (MDVs) formation, we rationally employed a gradient extrusion‐based strategy to fabricate biomimetic mitochondrial membrane vesicles (BMMVs), which enable efficient cartilage penetration and intrinsic mitochondrial targeting. Upon loading with the Sirtuin 3 (Sirt3) activator dihydromyricetin (DMY), the resulting DMY‐BMMVs effectively restore inflammation‑induced mitochondrial dysfunction and reprogram chondrocyte metabolism homeostasis. Furthermore, drawing inspiration from the hydration brush architecture of lubricin, PLL‑g‑PEG (polylysine‐g‐polyethylene glycol) is electrostatically assembled onto methacrylated hyaluronic acid (HAMA) microspheres to construct a bioinspired PEG brush interface. This lubricating microsphere system simultaneously serves as an intra‐articular delivery depot for DMY‐BMMVs, enabling sustained vesicle release while reconstructing the joint lubrication microenvironment. In vivo studies demonstrated that this integrated system markedly enhances cartilage regeneration, alleviates OA‐associated pain, and restores joint mobility. Overall, this work establishes a multifunctional materials‐driven platform that synergistically integrates mitochondrial‐targeted metabolic regulation with bioinspired interfacial lubrication, offering a new paradigm for OA treatment from a biomaterials engineering perspective.
- 10 August 2026
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (73) , e77452
Open AccessBiomimetic Mitochondrial Vesicles Delivered by Lubricative Hydrogel Microspheres Enable Cartilage Repair in Osteoarthritis
Mitochondrial dysfunction in chondrocytes and the loss of joint lubrication are increasingly recognized as key pathological drivers of functional deterioration in osteoarthritis (OA). However, the rational design of multifunctional biomaterials capable of concurrently regulating bioenergetic metabolism and the joint mechanical microenvironment remains highly challenging. Inspired by the natural process of mitochondrial‐derived vesicles (MDVs) formation, we rationally employed a gradient extrusion‐based strategy to fabricate biomimetic mitochondrial membrane vesicles (BMMVs), which enable efficient cartilage penetration and intrinsic mitochondrial targeting. Upon loading with the Sirtuin 3 (Sirt3) activator dihydromyricetin (DMY), the resulting DMY‐BMMVs effectively restore inflammation‑induced mitochondrial dysfunction and reprogram chondrocyte metabolism homeostasis. Furthermore, drawing inspiration from the hydration brush architecture of lubricin, PLL‑g‑PEG (polylysine‐g‐polyethylene glycol) is electrostatically assembled onto methacrylated hyaluronic acid (HAMA) microspheres to construct a bioinspired PEG brush interface. This lubricating microsphere system simultaneously serves as an intra‐articular delivery depot for DMY‐BMMVs, enabling sustained vesicle release while reconstructing the joint lubrication microenvironment. In vivo studies demonstrated that this integrated system markedly enhances cartilage regeneration, alleviates OA‐associated pain, and restores joint mobility. Overall, this work establishes a multifunctional materials‐driven platform that synergistically integrates mitochondrial‐targeted metabolic regulation with bioinspired interfacial lubrication, offering a new paradigm for OA treatment from a biomaterials engineering perspective.
- Open Access
- 21 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
The PLAGL1-KLF4-IRX5 axis promotes the osteogenesis of periosteal progenitors during mandible regeneration
Transcription factor (TF) networks are pivotal regulators of stem/progenitor cell fate. However, the regulatory mechanisms mediated by key TFs in adult periosteal stem/progenitor cells (PSPCs) remain poorly understood, impeding targeted therapies development for craniofacial bone regeneration. By integrating an analysis of regeneration-related, tissue-specific TF networks with insights from embryonic development, we demonstrate that the imprinted TF PLAGL1 is critical for the osteoblast differentiation of PSPCs and that the loss of Plagl1 compromises mandibular bone regeneration. Mechanistically, PLAGL1 transcriptionally activates TF Irx5 synergistically with TF KLF4, thereby inducing the expression of downstream osteogenic genes. Using the CRISPR-dCas9-Tet1-CD/sgRNA system, we develop a differentially methylated region-targeted therapeutic strategy to reactivate the maternal allele of Plagl1, leveraging its imprinted function to promote mandibular bone regeneration. This study delineates the PLAGL1-KLF4-IRX5 regulatory axis controlling osteoblast differentiation of PSPCs and further proposes an application strategy integrating TF modulation with epigenetic regulation for craniofacial bone regeneration.
- 21 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessThe PLAGL1-KLF4-IRX5 axis promotes the osteogenesis of periosteal progenitors during mandible regeneration
Transcription factor (TF) networks are pivotal regulators of stem/progenitor cell fate. However, the regulatory mechanisms mediated by key TFs in adult periosteal stem/progenitor cells (PSPCs) remain poorly understood, impeding targeted therapies development for craniofacial bone regeneration. By integrating an analysis of regeneration-related, tissue-specific TF networks with insights from embryonic development, we demonstrate that the imprinted TF PLAGL1 is critical for the osteoblast differentiation of PSPCs and that the loss of Plagl1 compromises mandibular bone regeneration. Mechanistically, PLAGL1 transcriptionally activates TF Irx5 synergistically with TF KLF4, thereby inducing the expression of downstream osteogenic genes. Using the CRISPR-dCas9-Tet1-CD/sgRNA system, we develop a differentially methylated region-targeted therapeutic strategy to reactivate the maternal allele of Plagl1, leveraging its imprinted function to promote mandibular bone regeneration. This study delineates the PLAGL1-KLF4-IRX5 regulatory axis controlling osteoblast differentiation of PSPCs and further proposes an application strategy integrating TF modulation with epigenetic regulation for craniofacial bone regeneration.
- Top Cited PapersOpen Access
- 19 January 2026
- Published by Springer Nature in Bone Research
- Vol. 14 (1) , 9
Neutrophil-initiated nociceptive ingrowth orchestrates inflammation resolution to potentiate bone regeneration
Nociceptive pain is a cardinal feature of traumatic and inflammatory bone diseases. However, whether and how nociceptors actively regulate the immune response during bone regeneration remains unclear. Here, we found that neutrophil-triggered nociceptive ingrowth functioned as negative feedback regulation to inflammation during bone healing. A unique Il4ra + Ccl2 high neutrophil subset drove intense postinjury TRPV1 + nociceptive ingrowth, which in return dissipated inflammation by activating the production of pro-resolving mediator lipoxin A4 (LXA4) in osteoblasts. Mechanistically, osteoblastic autophagy activated by nociceptor-derived calcitonin gene-related peptide (CGRP) suppressed the nuclear translocation of arachidonate 5-lipoxygenase (5-LOX) to favor the LXA4 biosynthesis. Moreover, in alveolar bone from patients with Type II diabetes, we found diminished nociceptive innervation correlated with reduced autophagy, increased inflammation, and impaired bone formation. Activating nociceptive nerves by spicy diet or topical administration of a clinical-approved TRPV1 agonist showed therapeutic benefits on alveolar bone healing in diabetic mice. These results reveal a critical neuroimmune interaction underlying the inflammation-regeneration balance during bone repairing and may lead to novel therapeutic strategies for inflammatory bone diseases.
- 19 January 2026
- Published by Springer Nature in Bone Research
- Vol. 14 (1) , 9
Top Cited PapersOpen AccessNeutrophil-initiated nociceptive ingrowth orchestrates inflammation resolution to potentiate bone regeneration
Nociceptive pain is a cardinal feature of traumatic and inflammatory bone diseases. However, whether and how nociceptors actively regulate the immune response during bone regeneration remains unclear. Here, we found that neutrophil-triggered nociceptive ingrowth functioned as negative feedback regulation to inflammation during bone healing. A unique Il4ra + Ccl2 high neutrophil subset drove intense postinjury TRPV1 + nociceptive ingrowth, which in return dissipated inflammation by activating the production of pro-resolving mediator lipoxin A4 (LXA4) in osteoblasts. Mechanistically, osteoblastic autophagy activated by nociceptor-derived calcitonin gene-related peptide (CGRP) suppressed the nuclear translocation of arachidonate 5-lipoxygenase (5-LOX) to favor the LXA4 biosynthesis. Moreover, in alveolar bone from patients with Type II diabetes, we found diminished nociceptive innervation correlated with reduced autophagy, increased inflammation, and impaired bone formation. Activating nociceptive nerves by spicy diet or topical administration of a clinical-approved TRPV1 agonist showed therapeutic benefits on alveolar bone healing in diabetic mice. These results reveal a critical neuroimmune interaction underlying the inflammation-regeneration balance during bone repairing and may lead to novel therapeutic strategies for inflammatory bone diseases.
- Open Access
- 25 September 2025
- Published by Springer Nature in International Journal of Oral Science
- Vol. 17 (1) , 1-13
PLAGL1-IGF2 axis regulates osteogenesis of postnatal condyle development
The mandibular condyle is a critical growth center in craniofacial bone development, especially during postnatal stages. Postnatal condyle osteogenesis requires precise spatiotemporal coordination of growth factor signaling cascades and hierarchical gene regulatory networks. Plagl1, which encodes a zinc finger transcription factor, is a paternally expressed gene. We demonstrate that PLAGL1 is highly expressed in cranial neural crest cell (CNCC)-derived lineage cells in mouse condyles. Using the CNCC-derived lineage-specific Plagl1 knockout mouse model, we evaluate the function of PLAGL1 during postnatal mouse condyle development. Our findings show that PLAGL1 contributes significantly to osteoblast differentiation, and its deficiency impairs osteogenic lineage differentiation, which consequently disrupts mandibular condyle development. Mechanistically, insulin-like growth factor 2 (IGF2) in complex with IGF-binding proteins (IGFBPs) has been identified as the principal PLAGL1 effector responsible for osteogenic regulation during postnatal condyle morphogenesis. Plagl1 deficiency significantly downregulates the IGF2/IGFBP pathway, leading to disordered glucose metabolism, defective extracellular matrix organization, and impaired ossification. Exogenous IGF2 treatment rescues impaired osteoblast differentiation caused by Plagl1 deficiency. In conclusion, the PLAGL1-IGF2 axis is a critical regulator of osteogenesis during mandibular condyle development.
- 25 September 2025
- Published by Springer Nature in International Journal of Oral Science
- Vol. 17 (1) , 1-13
Open AccessPLAGL1-IGF2 axis regulates osteogenesis of postnatal condyle development
The mandibular condyle is a critical growth center in craniofacial bone development, especially during postnatal stages. Postnatal condyle osteogenesis requires precise spatiotemporal coordination of growth factor signaling cascades and hierarchical gene regulatory networks. Plagl1, which encodes a zinc finger transcription factor, is a paternally expressed gene. We demonstrate that PLAGL1 is highly expressed in cranial neural crest cell (CNCC)-derived lineage cells in mouse condyles. Using the CNCC-derived lineage-specific Plagl1 knockout mouse model, we evaluate the function of PLAGL1 during postnatal mouse condyle development. Our findings show that PLAGL1 contributes significantly to osteoblast differentiation, and its deficiency impairs osteogenic lineage differentiation, which consequently disrupts mandibular condyle development. Mechanistically, insulin-like growth factor 2 (IGF2) in complex with IGF-binding proteins (IGFBPs) has been identified as the principal PLAGL1 effector responsible for osteogenic regulation during postnatal condyle morphogenesis. Plagl1 deficiency significantly downregulates the IGF2/IGFBP pathway, leading to disordered glucose metabolism, defective extracellular matrix organization, and impaired ossification. Exogenous IGF2 treatment rescues impaired osteoblast differentiation caused by Plagl1 deficiency. In conclusion, the PLAGL1-IGF2 axis is a critical regulator of osteogenesis during mandibular condyle development.
- Open Access
- 22 September 2025
- Published by Elsevier in Biomaterials
- Vol. 327, 123736
Advanced biomaterial-based strategies for craniofacial bone regeneration
- 22 September 2025
- Published by Elsevier in Biomaterials
- Vol. 327, 123736
Open AccessAdvanced biomaterial-based strategies for craniofacial bone regeneration
- Open Access
- 16 October 2024
- Published by Wiley in Advanced Science
- Vol. 11 (45) , e2404130
Programmed BRD9 Degradation and Hedgehog Signaling Activation via Silk‐Based Core‐Shell Microneedles Promote Diabetic Wound Healing
Wound healing impairment in diabetes mellitus is associated with an excessive inflammatory response and defective regeneration capability with suppressed Hedgehog (Hh) signaling. The bromodomain protein BRD9, a subunit of the non‐canonical BAF chromatin‐remodeling complex, is critical for macrophage inflammatory response. However, whether the epigenetic drug BRD9 degrader can attenuate the sustained inflammatory state of wounds in diabetes remains unclear. Without a bona fide immune microenvironment, Hh signaling activation fails to effectively rescue the suppressed proliferative ability of dermal fibroblasts and the vascularization of endothelial cells. Therefore, a silk‐based core‐shell microneedle (MN) patch is proposed to dynamically modulate the wound immune microenvironment and the regeneration process. Specifically, the BRD9 degrader released from the shell of the MNs mitigated the excessive inflammatory response in the early phase. Subsequently, the positively charged Hh signaling agonist is released from the negatively charged core of the silk fibroin nanofibers and promotes the phase transition from inflammation to regeneration, including re‐epithelialization, collagen deposition, and angiogenesis. These findings suggest that the programmed silk‐based core‐shell MN patch is an ideal therapeutic strategy for effective skin regeneration in diabetic wounds.
- 16 October 2024
- Published by Wiley in Advanced Science
- Vol. 11 (45) , e2404130
Open AccessProgrammed BRD9 Degradation and Hedgehog Signaling Activation via Silk‐Based Core‐Shell Microneedles Promote Diabetic Wound Healing
Wound healing impairment in diabetes mellitus is associated with an excessive inflammatory response and defective regeneration capability with suppressed Hedgehog (Hh) signaling. The bromodomain protein BRD9, a subunit of the non‐canonical BAF chromatin‐remodeling complex, is critical for macrophage inflammatory response. However, whether the epigenetic drug BRD9 degrader can attenuate the sustained inflammatory state of wounds in diabetes remains unclear. Without a bona fide immune microenvironment, Hh signaling activation fails to effectively rescue the suppressed proliferative ability of dermal fibroblasts and the vascularization of endothelial cells. Therefore, a silk‐based core‐shell microneedle (MN) patch is proposed to dynamically modulate the wound immune microenvironment and the regeneration process. Specifically, the BRD9 degrader released from the shell of the MNs mitigated the excessive inflammatory response in the early phase. Subsequently, the positively charged Hh signaling agonist is released from the negatively charged core of the silk fibroin nanofibers and promotes the phase transition from inflammation to regeneration, including re‐epithelialization, collagen deposition, and angiogenesis. These findings suggest that the programmed silk‐based core‐shell MN patch is an ideal therapeutic strategy for effective skin regeneration in diabetic wounds.
- Open Access
- 17 July 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-20
ARID1A safeguards the canalization of the cell fate decision during osteoclastogenesis
Chromatin remodeler ARID1A regulates gene transcription by modulating nucleosome positioning and chromatin accessibility. While ARID1A-mediated stage and lineage-restricted gene regulation during cell fate canalization remains unresolved. Using osteoclastogenesis as a model, we show that ARID1A transcriptionally safeguards the osteoclast (OC) fate canalization during proliferation-differentiation switching at single-cell resolution. Notably, ARID1A is indispensable for the transcriptional apparatus condensates formation with coactivator BRD4/lineage-specifying transcription factor (TF) PU.1 at Nfatc1 super-enhancer during safeguarding the OC fate canalization. Besides, the antagonist function between ARID1A-cBAF and BRD9-ncBAF complex during osteoclastogenesis has been validated with in vitro assay and compound mutant mouse model. Furthermore, the antagonistic function of ARID1A-“accelerator” and BRD9-“brake” both depend on coactivator BRD4-“clutch” during osteoclastogenesis. Overall, these results uncover sophisticated cooperation between chromatin remodeler ARID1A, coactivator, and lineage-specifying TF at super-enhancer of lineage master TF in a condensate manner, and antagonist between distinct BAF complexes in the proper and balanced cell fate canalization.
- 17 July 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-20
Open AccessARID1A safeguards the canalization of the cell fate decision during osteoclastogenesis
Chromatin remodeler ARID1A regulates gene transcription by modulating nucleosome positioning and chromatin accessibility. While ARID1A-mediated stage and lineage-restricted gene regulation during cell fate canalization remains unresolved. Using osteoclastogenesis as a model, we show that ARID1A transcriptionally safeguards the osteoclast (OC) fate canalization during proliferation-differentiation switching at single-cell resolution. Notably, ARID1A is indispensable for the transcriptional apparatus condensates formation with coactivator BRD4/lineage-specifying transcription factor (TF) PU.1 at Nfatc1 super-enhancer during safeguarding the OC fate canalization. Besides, the antagonist function between ARID1A-cBAF and BRD9-ncBAF complex during osteoclastogenesis has been validated with in vitro assay and compound mutant mouse model. Furthermore, the antagonistic function of ARID1A-“accelerator” and BRD9-“brake” both depend on coactivator BRD4-“clutch” during osteoclastogenesis. Overall, these results uncover sophisticated cooperation between chromatin remodeler ARID1A, coactivator, and lineage-specifying TF at super-enhancer of lineage master TF in a condensate manner, and antagonist between distinct BAF complexes in the proper and balanced cell fate canalization.
- Open Access
- 14 March 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-20
BRD9-mediated chromatin remodeling suppresses osteoclastogenesis through negative feedback mechanism
Bromodomain-containing protein 9 (BRD9), a component of non-canonical BAF chromatin remodeling complex, has been identified as a critical therapeutic target in hematological diseases. Despite the hematopoietic origin of osteoclasts, the role of BRD9 in osteoclastogenesis and bone diseases remains unresolved. Here, we show Brd9 deficiency in myeloid lineage enhances osteoclast lineage commitment and bone resorption through downregulating interferon-beta (IFN-β) signaling with released constraint on osteoclastogenesis. Notably, we show that BRD9 interacts with transcription factor FOXP1 activating Stat1 transcription and IFN-β signaling thereafter. Besides, function specificity of BRD9 distinguished from BRD4 during osteoclastogenesis has been evaluated. Leveraging advantages of pharmacological modulation of BRD9 and flexible injectable silk fibroin hydrogel, we design a local deliver system for effectively mitigating zoledronate related osteonecrosis of the jaw and alleviating acute bone loss in lipopolysaccharide-induced localized aggressive periodontitis. Overall, these results demonstrate the function of BRD9 in osteoclastogenesis and its therapeutic potential for bone diseases.
- 14 March 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-20
Open AccessBRD9-mediated chromatin remodeling suppresses osteoclastogenesis through negative feedback mechanism
Bromodomain-containing protein 9 (BRD9), a component of non-canonical BAF chromatin remodeling complex, has been identified as a critical therapeutic target in hematological diseases. Despite the hematopoietic origin of osteoclasts, the role of BRD9 in osteoclastogenesis and bone diseases remains unresolved. Here, we show Brd9 deficiency in myeloid lineage enhances osteoclast lineage commitment and bone resorption through downregulating interferon-beta (IFN-β) signaling with released constraint on osteoclastogenesis. Notably, we show that BRD9 interacts with transcription factor FOXP1 activating Stat1 transcription and IFN-β signaling thereafter. Besides, function specificity of BRD9 distinguished from BRD4 during osteoclastogenesis has been evaluated. Leveraging advantages of pharmacological modulation of BRD9 and flexible injectable silk fibroin hydrogel, we design a local deliver system for effectively mitigating zoledronate related osteonecrosis of the jaw and alleviating acute bone loss in lipopolysaccharide-induced localized aggressive periodontitis. Overall, these results demonstrate the function of BRD9 in osteoclastogenesis and its therapeutic potential for bone diseases.
- 6 August 2018
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 10 (34) , 28340-28350
Time-Phase Sequential Utilization of Adipose-Derived Mesenchymal Stem Cells on Mesoporous Bioactive Glass for Restoration of Critical Size Bone Defects
The effective transportation of oxygen, nutrients, and metabolic wastes through new blood vessel networks is key to the survival of engineered constructs in large bone defects. Adipose-derived mesenchymal stem cells (ADSCs), which are regarded as excellent candidates for both bone and blood vessel engineering, are the preferred option for the restoration of massive bone defects. Therefore, we propose to induce ADSCs into osteogenic and endothelial cells differently. A modified hierarchical mesoporous bioactive glass (MBG) scaffold with an enhanced compressive strength was constructed and prevascularized by seeding with endothelial-induced ADSCs (EI-ADSCs). The prevascularized scaffolds were combined with osteogenically induced ADSCs (OI-ADSCs) to repair critical-size bone defects. To validate the angiogenesis of the prevascularized MBG scaffolds in vivo, green fluorescent protein (GFP) was used to label EI-ADSCs. The labeled EI-ADSCs were demonstrated to survive and participate in vascularization at day 7 after subcutaneous implantation in nude mice by double immunofluorescence staining of CD31 and GFP. Regarding the restoration of critical size bone defects, early angiogenesis of rat femur plug defects was evaluated by perfusion of Microfil after 3 weeks. Compared to nonvascularized MBG carrying OI-ADSCs (MBG/OI-ADSCs) and non-cell-seeded MBG scaffolds, the prevascularized MBG carrying OI-ADSCs (Pv-MBG/OI-ADSCs) showed enhanced angiogenesis on the surface and interior. Through dynamic bone formation analysis with sequential fluorescent labeling and Van Gieson’s picro-fuchsin staining, we found that the Pv-MBG/OI-ADSCs exhibited the highest mineral deposition rate after surgery, which may be contributed by rapid vascular anastomosis facilitating increased survival of the seeded OI-ADSCs and by the recruitment function for bone mesenchymal stem cells. Therefore, the strategy of time-phase sequential utilization of ADSCs on MBG scaffolds is a practical design for the repair of massive bone defects.
- 6 August 2018
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 10 (34) , 28340-28350
Time-Phase Sequential Utilization of Adipose-Derived Mesenchymal Stem Cells on Mesoporous Bioactive Glass for Restoration of Critical Size Bone Defects
The effective transportation of oxygen, nutrients, and metabolic wastes through new blood vessel networks is key to the survival of engineered constructs in large bone defects. Adipose-derived mesenchymal stem cells (ADSCs), which are regarded as excellent candidates for both bone and blood vessel engineering, are the preferred option for the restoration of massive bone defects. Therefore, we propose to induce ADSCs into osteogenic and endothelial cells differently. A modified hierarchical mesoporous bioactive glass (MBG) scaffold with an enhanced compressive strength was constructed and prevascularized by seeding with endothelial-induced ADSCs (EI-ADSCs). The prevascularized scaffolds were combined with osteogenically induced ADSCs (OI-ADSCs) to repair critical-size bone defects. To validate the angiogenesis of the prevascularized MBG scaffolds in vivo, green fluorescent protein (GFP) was used to label EI-ADSCs. The labeled EI-ADSCs were demonstrated to survive and participate in vascularization at day 7 after subcutaneous implantation in nude mice by double immunofluorescence staining of CD31 and GFP. Regarding the restoration of critical size bone defects, early angiogenesis of rat femur plug defects was evaluated by perfusion of Microfil after 3 weeks. Compared to nonvascularized MBG carrying OI-ADSCs (MBG/OI-ADSCs) and non-cell-seeded MBG scaffolds, the prevascularized MBG carrying OI-ADSCs (Pv-MBG/OI-ADSCs) showed enhanced angiogenesis on the surface and interior. Through dynamic bone formation analysis with sequential fluorescent labeling and Van Gieson’s picro-fuchsin staining, we found that the Pv-MBG/OI-ADSCs exhibited the highest mineral deposition rate after surgery, which may be contributed by rapid vascular anastomosis facilitating increased survival of the seeded OI-ADSCs and by the recruitment function for bone mesenchymal stem cells. Therefore, the strategy of time-phase sequential utilization of ADSCs on MBG scaffolds is a practical design for the repair of massive bone defects.